Because I’m a bit of a nerd about health and medicine, I listen to different podcasts on those topics. Increasingly on medical themed podcasts I’m hearing doctors discuss breakthroughs that are happening due to AI.
For example, recently, an AI software created a new type of anti-biotic. This is noteworthy because over time, the effectiveness of existing anti-biotics has been decreasing and viruses are mutating and becoming resistant to them. So we need to adapt and innovate as well, but it seems inventing new anti-biotics is hard, because as this report states, this was the first new class of anti-biotics developed in over 60 years!
Then there was the study showing AI was more accurate at diagnosing than GPs.
And the study where AI was able to identify early markers for prostate cancer, one of the deadliest cancers we have. According to this report, researchers in Melbourne ” have developed a diagnostic tool that can spot prostate cancer before patients have any symptoms, using artificial intelligence to analyse CT scans in just seconds“. Improving early detection could be an absolute game changer for prostate cancer.
Which segues nicely into todays post. C The Signs is a new AI diagnostic tool being used to improve early detection of a number of different types of cancer. The AI model works by “analyzing data already available in patient electronic health records, going beyond basic risk indicators like age and gender, to examine a wide number of personal and environmental data points to precisely assess an individual’s cancer risk. By personalizing risk profiles, the platform flags people who need targeted testing and rules out those who do not, reducing the burden on primary care physicians.”
How effective is it?
“It has identified 20.7% of breast cancer cases UP TO FIVE YEARS EARLIER than standard pathways, as well as beating early-stage diagnoses of ovarian cancer using traditional methods by 53.3%.”
“C the Signs also recently unveiled new data at the 2025 ASCO Gastrointestinal Cancers Symposium using its AI model on the records of 894,275 patients registered in the Mayo Data Platform to achieve a sensitivity of 93.8% – comparable to the sensitivity level of a colonoscopy – and a specificity of 19.7% in identifying patients at risk of colorectal cancer. By detecting tumors when they can still be treated at stage 1 or 2, C the Signs increases survival odds compared to later-stage diagnoses.”
Did they just say it’s about as accurate as a colonoscopy!?! Incredible!
Furthermore, the researchers noted “29.4% of patients with colorectal cancer were identified as being at risk UP TO 5 YEARS EARLIER by C the Signs compared to diagnoses made by primary care physicians, highlighting the platform’s potential for early detection.”
This technology is advancing at an incredible rate and we can’t wait to see what the next discovery involves! And if you want to listen to the podcast I listened to, click this link.
